M

MacroGenics

D
MGNX
USD
0.085
(2.5758%)
Market Closed
15,639.00
Volume
-1.72
EPS
-
Div Yield
-1.545662
P/E
212,314,795.94
Market Cap
Today
2.5758%
1 Week
-6.233%
1 Month
-4.916%
6 Months
-78.273%
12 Months
-26.253%
Year To Date
-64.813%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
AMGN
AMGN
3.02
(0.9071%)
USD
G
GNK
0.465
(2.6249%)
USD
M
MNK
-0.0649
(-16.0683%)
USD
GSK
GSK
-0.78
(-1.8383%)
USD
N
NVAX
-0.01
(-0.0796%)
USD
AZN
AZN
0.32
(0.4072%)
USD
E
EXAS
1.61
(2.3256%)
USD
S
SGEN
(%)
USD
PFE
PFE
-0.09
(-0.3025%)
USD
MRK
MRK
-1.44
(-1.2137%)
USD
BMY
BMY
-0.72
(-1.4475%)
USD

Title:
MacroGenics

Sector:
Healthcare
Industry:
Biotechnology
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 CTLA-4), Tebotelimab (PD-1 LAG-3), MGD024 (CD123 CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV CD3).
Do you need help or have a question?
Contact Us